Literature DB >> 21863318

Symptomatic myocarditis in Kawasaki disease.

Pooja Aggarwal1, Deepti Suri, Nidhi Narula, Rohit Manojkumar, Surjit Singh.   

Abstract

Kawasaki disease (KD) is an acute febrile illness of infants and young children that is characterized by a medium vessel vasculitis, most commonly involving the coronary arteries. Though subclinical myocarditis is rather common in KD, symptomatic congestive heart failure is extremely uncommon. The authors report a 9-y-old boy who developed heart failure (ejection fraction 28%) in the acute phase of KD. He was initially treated with intravenous immunoglobulin (2 g/kg) without much clinical improvement. He was then given 5 daily pulses of intravenous methylprednisolone followed by tapering doses of oral prednisolone. The child showed prompt clinical recovery and remains well on follow-up. The present case serves to highlight the fact that methylprednisolone can be considered upfront as rescue therapy in children with KD who have symptomatic congestive cardiac failure during the acute stage of the disease.

Entities:  

Mesh:

Year:  2011        PMID: 21863318     DOI: 10.1007/s12098-011-0552-4

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  8 in total

1.  Impressions of Kawasaki syndrome in India.

Authors:  Howard I Kushner; Rupert Macnee; Jane C Burns
Journal:  Indian Pediatr       Date:  2006-11       Impact factor: 1.411

2.  Four cases of Kawasaki syndrome complicated with myocarditis.

Authors:  Hideki Yoshikawa; Yuichi Nomura; Kiminori Masuda; Daisuke Hazeki; Keiko Yotsumoto; Michiko Arata; Akira Kamenosono; Sadamitsu Yanagi; Masao Yoshinaga; Yoshifumi Kawano
Journal:  Circ J       Date:  2006-02       Impact factor: 2.993

3.  A comparison of the clinical profile of Kawasaki disease in children from Northern India above and below 5 years of age.

Authors:  S Singh; M K Gupta; A Bansal; R M Kumar; B R Mittal
Journal:  Clin Exp Rheumatol       Date:  2007 Jul-Aug       Impact factor: 4.473

4.  Myocarditis in Kawasaki syndrome. A minor villain?

Authors:  M Takahashi
Journal:  Circulation       Date:  1989-06       Impact factor: 29.690

5.  Kawasaki disease: cardiac problems and management.

Authors:  H Kato; O Inoue; T Akagi
Journal:  Pediatr Rev       Date:  1988-01

6.  Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.

Authors:  Jane W Newburger; Lynn A Sleeper; Brian W McCrindle; L LuAnn Minich; Welton Gersony; Victoria L Vetter; Andrew M Atz; Jennifer S Li; Masato Takahashi; Annette L Baker; Steven D Colan; Paul D Mitchell; Gloria L Klein; Robert P Sundel
Journal:  N Engl J Med       Date:  2007-02-15       Impact factor: 91.245

7.  Circulating cardiac troponin I levels in Kawasaki disease.

Authors:  P A Checchia; J Borensztajn; S T Shulman
Journal:  Pediatr Cardiol       Date:  2001 Mar-Apr       Impact factor: 1.655

8.  Kawasaki disease.

Authors:  Jane W Newburger; David R Fulton
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-04
  8 in total
  3 in total

1.  Myocardial Strain and Strain Rate in Kawasaki Disease: Range, Recovery, and Relationship to Systemic Inflammation/Coronary Artery Dilation.

Authors:  Benjamin Frank; Jesse Davidson; Suhong Tong; Blake Martin; Heather Heizer; Marsha S Anderson; Mary P Glode; Samuel R Dominguez; Pei-Ni Jone
Journal:  J Clin Exp Cardiolog       Date:  2016-04-21

2.  Recent Experience: Corticosteroids as a First-line Therapy in Children With Multisystem Inflammatory Syndrome and COVID-19-related Myocardial Damage.

Authors:  Vladislav Vukomanovic; Stasa Krasic; Sergej Prijic; Sanja Ninic; Sasa Popovic; Gordana Petrovic; Snezana Ristic; Radoje Simic; Ivana Cerovic; Dejan Nesic
Journal:  Pediatr Infect Dis J       Date:  2021-11-01       Impact factor: 3.806

3.  Multisystem Inflammatory Syndrome with Features of Atypical Kawasaki Disease during COVID-19 Pandemic.

Authors:  Abdul Rauf; Ajay Vijayan; Shaji Thomas John; Raghuram Krishnan; Abdul Latheef
Journal:  Indian J Pediatr       Date:  2020-05-28       Impact factor: 1.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.